Senior Investigator Dr. Mark Gladwin leads the Sickle Cell/Nitric Oxide
Therapeutic Section in the Critical Care Medicine Department at the NIH Clinical Center.
His research endeavors focus on understanding the role of lung complications in adults
with sickle cell disease and evaluating the role of current (hydroxyurea) and future
(nitric oxide) therapies in sickle cell disease treatment.
After receiving his Bachelor of Science and Doctor of Medicine degrees at the
University of Miami he completed an internship and chief residency in internal medicine
at the Oregon Health Sciences University in Portland, Oregon. He then served in three
fellowships, as a Critical Care Fellow with the Critical Care Medicine Department at
the NIH Clinical Center; a Pulmonary-Critical Care Fellow in the Pulmonary Division
of the University of Washington in Seattle; and as a Senior Research Fellow in
critical care medicine, returning to NIH in 1998. From 1995 to 2000 Dr. Gladwin
was on active duty as a Commander in the U. S. Public Health Service Commissioned Corps.
He has served as Section Head for the Sickle Cell/Nitric Oxide Therapeutic Section with
the NIH Clinical Center's Critical Care Medicine department since 2001.
Dr. Gladwin's awards and accolades cover mentoring, teaching and scholarship. These include
academic merit and honors scholarships from the University of Miami and teaching awards from the
Oregon Health Sciences University and professional organizations such as the American College of
Physicians, American Thoracic Society and American Heart Association. His mentoring and research
leadership efforts have been recognized by the Fellowship Program in Academic Medicine for Minority
Students, the Clinical Center and NIH.
As founder and director of the Unity Healthcare Asthma/Pulmonary Clinic Mission in Washington,
D.C., Dr. Gladwin delivers pulmonary subspecialty care to homeless and indigent patients through
two community clinics. With the support of NIH's Office for Research in Minority Health and the
Clinical Center's Critical Care Medicine Department he has established programmatic relationships
between minority patients and NIH clinical research protocols
He is the principal or associate investigator on more than a half dozen concurrent studies
researching potential interventional therapies for the management of sickle cell disease symptoms
and complications. He has received research grants from NIH's Office for Research in Minority Health
and both the Bench-to-Bedside and Cooperative Research and Development Agreement programs.
A prolific lecturer and writer, Dr. Gladwin is recognized as a diplomat in Pulmonary Disease
with the American Board of Pulmonary Medicine and in Critical Care Medicine with the American
Board of Critical Care Medicine, and is board certified as an internal medicine specialist.
Medicine
for the Public home
|
